On 15 July 2021, Medlive Technology Co., Ltd. (Medlive Technology) made its IPO on the Main Board of the Hong Kong Stock Exchange under the stock code: 2192.HK. Medlive Technology issued 155,096,000 shares (subject to over-allotment) in this global offering at an issue price of HKD27.20 per share, raising a total of approximately HKD 4.001 billion (subject to over-allotment).
Medlive Technology focuses on building an excellent Internet doctor platform and using scientific and technological innovations to help doctors make better clinical decisions. Its self-developed "Medlive Platform" is widely recognised by Chinese doctors and has become the preferred choice of pharmaceutical and medical equipment companies in China for precision digital medical marketing.
King & Wood Mallesons (KWM) acted as the PRC legal counsel for the sponsors, Goldman Sachs (Asia) L.L.C. and Haitong International Capital Limited. KWM fully participated in the project in terms of structure design, PRC legal due diligence, business due diligence, review and revision of prospectus. KWM provided comprehensive, professional, high-quality and efficient services to help Medlive Technology successfully complete this IPO.
The project was led by partners Jiang Yifeng, Sun Ji, and Hu Qian. Other team members included Wang Kun, Dong Yajing and Chen Suyi.